Oxytocin acetate is the acetate salt of oxytocin, a cyclic nonapeptide with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 and a disulfide bridge between the two cysteines. The free peptide has a molecular weight of about 1,007 Da. It is studied in vitro as the reference agonist of the oxytocin receptor, a Gq-coupled G protein-coupled receptor (GPCR), and as a model disulfide-containing peptide for analytical and stability work. This article covers its structure, mechanism, published research, laboratory applications and the handling requirements that affect data quality.
What is oxytocin acetate?
Oxytocin is a neurohypophysial peptide hormone synthesised mainly in magnocellular neurons of the hypothalamic paraventricular and supraoptic nuclei. The mature peptide contains nine amino acids: cysteine, tyrosine, isoleucine, glutamine, asparagine, cysteine, proline, leucine and glycine, with an amidated C-terminus. The two cysteines at positions 1 and 6 form an intramolecular disulfide bond, which creates a six-residue ring and leaves a three-residue tail (Pro-Leu-Gly-NH2). The formula is C43H66N12O12S2, and the molecular weight is about 1,007.2 Da.
Oxytocin acetate is this peptide supplied with acetate counter-ions bound to its basic groups. The sequence is identical to that of the free peptide, but the salt form affects the weight of the powder, its solubility and its net peptide content. Acetate is generally preferred over trifluoroacetate in cell-based work, because residual trifluoroacetate from HPLC purification can interfere with viability and signalling assays. Research-grade material of this kind is a different regulatory category from licensed pharmaceutical preparations of oxytocin, and the two should not be confused.
The history of the molecule runs through the early twentieth century. Henry Dale reported in 1906 that extracts of the posterior pituitary stimulated contraction of the uterus, and Ott and Scott described the milk-ejecting action of such extracts a few years later. Vincent du Vigneaud and colleagues then determined the structure and, in 1953, reported the first chemical synthesis of an octapeptide amide with the hormonal activity of oxytocin, in the Journal of the American Chemical Society. This was the first synthesis of a peptide hormone, and it earned du Vigneaud the 1955 Nobel Prize in Chemistry.
Oxytocin is closely related to vasopressin, which has the same ring size and C-terminal tail but differs at positions 3 and 8. The structural similarity explains why oxytocin has measurable affinity for vasopressin receptors, a point that matters when designing selectivity controls.
Mechanism of action
Oxytocin acts through the oxytocin receptor (OXTR), a class A GPCR. According to a major review by Gimpl and Fahrenholz, the receptor couples primarily through Gq proteins to phospholipase C-β. Activation of this enzyme cleaves phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and diacylglycerol activates protein kinase C. In smooth muscle and other responsive cells, the rise in intracellular calcium drives the downstream response, and the receptor can also signal through other routes, including MAPK/ERK and, in some systems, Gi.
Two features of the receptor are important in assay design. The first is that its high-affinity state requires magnesium and cholesterol, which probably function as allosteric modulators. A cryo-EM structure of human OXTR bound to oxytocin and a Gq protein, published by Meyerowitz and colleagues in 2022, showed a magnesium coordination complex between the hormone and the receptor and a disruption of transmembrane helix 7 on activation. The same study found that a single cation-coordinating residue determines whether a vasopressin-family receptor depends on magnesium. Assay buffers for OXTR work should therefore contain magnesium, and membrane preparations or cell systems depleted of cholesterol may show reduced affinity.
The second is cross-reactivity. Oxytocin binds vasopressin V1a and V2 receptors with lower affinity, and it is a full agonist at OXTR but may act as a partial agonist elsewhere. Cell lines expressing several receptors, or tissues with mixed receptor populations, can give mixed responses, and selective antagonists and receptor-null controls help to separate them. Receptor expression levels, desensitisation and internalisation after prolonged exposure also affect dose-response curves, so exposure times should be defined and reported.
What the research shows
Four sets of published work frame the field.
The first is the chemical synthesis. Du Vigneaud and colleagues reported in 1953 that the synthesised peptide, built from protected amino acids and then cyclised by oxidation of the cysteine thiols, reproduced the biological activity of the natural hormone. This confirmed the proposed structure and showed that peptide hormones could be made in the laboratory.
The second is the comprehensive review of the receptor system by Gimpl and Fahrenholz in Physiological Reviews in 2001. It describes the receptor as a typical class I (rhodopsin-like) GPCR coupled to Gq and phospholipase C-β, notes the requirement for magnesium and cholesterol, and brings together evidence from molecular biology, mutagenesis and transgenic mice, including the observation that oxytocin-deficient mice confirm an essential role for the hormone in the milk let-down reflex. It is indexed on PubMed.
The third is the structural study of activation. Meyerowitz and colleagues, in Nature Structural & Molecular Biology in 2022, determined the cryo-EM structure of wild-type human OXTR bound to oxytocin and a miniGq protein at 2.9 Å. The structure revealed the magnesium coordination complex, the disruption of transmembrane helix 7, and the molecular basis for full agonism by oxytocin and partial agonism by analogues. The paper is available on PubMed.
The fourth is a research area, not a single paper: the degradation chemistry of oxytocin in solution. Kinetic studies of the peptide in aqueous formulations have identified deamidation of the glutamine and asparagine residues, disulfide scrambling and formation of dimers and larger aggregates as the main degradation pathways, and have reported that stability depends strongly on pH, with a maximum in the slightly acidic range around pH 4 to 5. Readers should consult the original kinetic papers for the conditions that apply to their own buffers.
Research applications
Receptor pharmacology is the main use. Cell lines such as HEK293 or CHO expressing human OXTR are stimulated with oxytocin, and responses are measured by calcium mobilisation with fluorescent indicators, inositol monophosphate (IP1) accumulation, ERK phosphorylation or β-arrestin recruitment. The peptide serves as the reference full agonist against which new ligands, antagonists and biased agonists are ranked. Competition binding assays with radiolabelled or fluorescent ligands use unlabelled oxytocin to define affinity and non-specific binding.
Isolated tissue and primary cell work is a second area. Smooth muscle preparations and cultured myometrial cells respond to oxytocin with contraction or calcium transients, and such preparations were the basis of classical potency bioassays before chromatographic methods became standard. Neuroscience research is a third, in which animal studies of oxytocin signalling, carried out by licensed investigators under the Animals (Scientific Procedures) Act 1986, examine receptor distribution and neuronal circuits.
Analytical chemistry is a fourth area. Oxytocin is a standard small cyclic peptide for HPLC and mass spectrometry method development, particularly for disulfide-containing molecules, and it is a convenient model for forced-degradation studies that map deamidation, oxidation and aggregation. Structure-activity research is a fifth, in which the native sequence is compared with analogues that carry substitutions in the ring or tail to explore how receptor selectivity and agonist efficacy arise.
Purity, storage and handling
Verification begins with reversed-phase HPLC, usually monitored at 214 or 220 nm, with purity commonly specified at 98% or above. Mass spectrometry should confirm the intact mass, with a monoisotopic [M+H]⁺ ion expected at about m/z 1007.4. Several impurities need specific attention. Deamidated forms and oxytocin free acid are both about 1 Da heavier than the amide, so they cannot be told apart by low-resolution mass alone and must be resolved chromatographically. Dimers, reduced (open-ring) peptide and disulfide-scrambled species also occur. Net peptide content is a separate figure, because the powder contains acetate counter-ions and water, and gross weight overstates the active amount.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Oxytocin Acetate should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers asking How to buy best peptides can use those documentation requirements as a first filter when comparing vendors.
A batch-specific certificate matters because disulfide-containing peptides are sensitive to the oxidation step and to handling after synthesis, so the proportion of dimers and scrambled forms can differ between batches. The certificate should give the batch number, HPLC conditions and chromatogram, the observed mass, the acetate content, the net peptide content and the test date. A figure for related substances, with identified impurities, is more informative than a single purity number.
Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening so that moisture does not condense on the powder. After reconstitution the peptide is much less stable, and oxytocin in solution is known to be sensitive to temperature as well as pH. Stock solutions are therefore usually prepared in a slightly acidic, buffered diluent, kept at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles, with low-binding tubes preferred for dilute working solutions. Exact stability windows depend on buffer, pH and concentration, so they should be taken from supplier data and confirmed in-house for critical assays. Neutral or alkaline buffers, which favour deamidation and disulfide exchange, should be introduced only at the time of the assay.
Light sensitivity is modest. The sequence has one tyrosine and no tryptophan, so it is less photolabile than many peptides, but amber vials or dark storage remain good practice. Reducing agents such as dithiothreitol will open the disulfide ring and inactivate the peptide, so they should be excluded from buffers. Standard COSHH assessment and institutional waste procedures apply.
Frequently asked questions
What is oxytocin acetate?
Oxytocin acetate is the acetate salt of oxytocin, a cyclic nonapeptide with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 and a disulfide bridge between the two cysteines. The free peptide weighs about 1,007 Da. It is supplied as a lyophilised powder for in-vitro receptor, signalling and analytical research.
What is the difference between oxytocin and oxytocin acetate?
The peptide sequence is identical. Oxytocin acetate carries acetate counter-ions that balance the positive charges on the peptide, which changes the weight of the powder, its solubility and its net peptide content. Concentrations should be calculated from net peptide content and not from gross vial weight.
How should lyophilised oxytocin acetate be stored?
Lyophilised oxytocin acetate is generally stored at -20°C in a sealed, desiccated container protected from light, and warmed to room temperature before opening. Reconstituted solutions are usually kept in slightly acidic buffer at 2-8°C for short periods as single-use aliquots, with stability limits confirmed from batch documentation.
What receptor does oxytocin act on, and does it need magnesium?
Oxytocin acts on the oxytocin receptor, a class A GPCR that couples mainly to Gq and phospholipase C-β. High-affinity binding needs magnesium and cholesterol, and a 2022 cryo-EM structure showed a magnesium coordination complex between the hormone and receptor, so assay buffers should contain magnesium.
Oxytocin acetate is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.